141 related articles for article (PubMed ID: 20543711)
21. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH
Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353
[TBL] [Abstract][Full Text] [Related]
22. Association between neuropeptide Y gene and its receptor Y1 gene and methamphetamine dependence.
Okahisa Y; Ujike H; Kotaka T; Morita Y; Kodama M; Inada T; Yamada M; Iwata N; Iyo M; Sora I; Ozaki N; Kuroda S
Psychiatry Clin Neurosci; 2009 Jun; 63(3):417-22. PubMed ID: 19566775
[TBL] [Abstract][Full Text] [Related]
23. ACE and AGTR1 polymorphisms and left ventricular hypertrophy in endurance athletes.
Di Mauro M; Izzicupo P; Santarelli F; Falone S; Pennelli A; Amicarelli F; Calafiore AM; Di Baldassarre A; Gallina S
Med Sci Sports Exerc; 2010 May; 42(5):915-21. PubMed ID: 19997001
[TBL] [Abstract][Full Text] [Related]
24. Adiponectin is associated with brain natriuretic peptide and left ventricular hypertrophy in hemodialysis patients with type 2 diabetes mellitus.
Komaba H; Igaki N; Goto S; Yokota K; Takemoto T; Hirosue Y; Goto T
Nephron Clin Pract; 2007; 107(3):c103-8. PubMed ID: 17890872
[TBL] [Abstract][Full Text] [Related]
25. Effects of the neuropeptide Y Y2 receptor antagonist BIIE0246 on sympathetic transmitter release in the pig in vivo.
Malmström RE; Lundberg JN; Weitzberg E
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):106-11. PubMed ID: 11819028
[TBL] [Abstract][Full Text] [Related]
26. Venous neuropeptide Y receptor responsiveness in patients with chronic heart failure.
Feng Q; Lambert ML; Callow ID; Arnold JM
Clin Pharmacol Ther; 2000 Mar; 67(3):292-8. PubMed ID: 10741633
[TBL] [Abstract][Full Text] [Related]
27. [Left ventricular hypertrophy in patient on dialysis].
Lovcić V; Sebetić D; Klobucić M; Kusec V
Acta Med Croatica; 2003; 57(1):61-4. PubMed ID: 12876866
[TBL] [Abstract][Full Text] [Related]
28. Differential suppression of seizures via Y2 and Y5 neuropeptide Y receptors.
Woldbye DP; Nanobashvili A; Sørensen AT; Husum H; Bolwig TG; Sørensen G; Ernfors P; Kokaia M
Neurobiol Dis; 2005 Dec; 20(3):760-72. PubMed ID: 15979311
[TBL] [Abstract][Full Text] [Related]
29. [Interaction analysis in epidemiological research].
D'Arrigo G; Provenzano F; Zoccali C; Tripepi G
G Ital Nefrol; 2011; 28(4):431-5. PubMed ID: 21809313
[No Abstract] [Full Text] [Related]
30. Relationship of BsmI polymorphism of vitamin D receptor gene with left ventricular hypertrophy and atherosclerosis in hemodialysis patients.
El-Shehaby AM; El-Khatib MM; Marzouk S; Battah AA
Scand J Clin Lab Invest; 2013 Feb; 73(1):75-81. PubMed ID: 23198772
[TBL] [Abstract][Full Text] [Related]
31. Neuropeptide Y gene functional polymorphism influences susceptibility to hypertension in Indian population.
Bhaskar LV; Thangaraj K; Non AL; Praveen Kumar K; Pardhasaradhi G; Singh L; Rao VR
J Hum Hypertens; 2010 Sep; 24(9):617-22. PubMed ID: 20033074
[TBL] [Abstract][Full Text] [Related]
32. Plasma neuropeptide Y during dynamic exercise in patients with essential hypertension.
Pruszczyk P; Chlebus M
Clin Exp Hypertens; 1995 Jul; 17(5):769-85. PubMed ID: 7655447
[TBL] [Abstract][Full Text] [Related]
33. Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENPP1 gene and left ventricular concentric remodelling.
Spoto B; Testa A; Parlongo RM; Tripepi G; Trischitta V; Mallamaci F; Zoccali C
Nephrol Dial Transplant; 2012 Feb; 27(2):661-6. PubMed ID: 21602183
[TBL] [Abstract][Full Text] [Related]
34. [Evaluation of plasma neuropeptide Y levels in patients with congestive heart failure].
Liu JJ; Shi SG; Han QD
Zhonghua Nei Ke Za Zhi; 1994 Oct; 33(10):687-9. PubMed ID: 7712919
[TBL] [Abstract][Full Text] [Related]
35. Plasma neuropeptide Y levels differ in distinct diabetic conditions.
Ilhan A; Rasul S; Dimitrov A; Handisurya A; Gartner W; Baumgartner-Parzer S; Wagner L; Kautzky-Willer A; Base W
Neuropeptides; 2010 Dec; 44(6):485-9. PubMed ID: 20832114
[TBL] [Abstract][Full Text] [Related]
36. [Influence of different blood purification treatment on the serum leptin and neuropeptide Y levels in patients with chronic renal failure].
Song J; Li H; Zhang XD
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Nov; 26(11):1116-8. PubMed ID: 21322279
[TBL] [Abstract][Full Text] [Related]
37. Reappraisal in two European cohorts of the prognostic power of left ventricular mass index in chronic kidney failure.
Tripepi G; Pannier B; D'Arrigo G; Mallamaci F; Zoccali C; London G
Kidney Int; 2017 Mar; 91(3):704-710. PubMed ID: 28010886
[TBL] [Abstract][Full Text] [Related]
38. Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease.
Zoccali C; Mallamaci F; Tripepi G; Benedetto FA; Parlongo S; Cutrupi S; Iellamo D; Bonanno G; Rapisarda F; Fatuzzo P; Seminara G; Cataliotti A; Malatino LS
J Am Soc Nephrol; 2003 Oct; 14(10):2611-7. PubMed ID: 14514739
[TBL] [Abstract][Full Text] [Related]
39. Neuropeptide Y associated with asthma in young adults.
Lu Y; Andiappan AK; Lee B; Ho R; Lim TK; Kuan WS; Goh DY; Mahadevan M; Sim TB; Wang Y; Van Bever HP; Rotzschke O; Larbi A; Ng TP
Neuropeptides; 2016 Oct; 59():117-121. PubMed ID: 27469060
[TBL] [Abstract][Full Text] [Related]
40. The 1258 G>A polymorphism in the neuropeptide Y gene is associated with greater alcohol consumption in a Mediterranean population.
Francès F; Guillen M; Verdú F; Portolés O; Castelló A; Sorlí JV; Corella D
Alcohol; 2011 Mar; 45(2):131-6. PubMed ID: 21303710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
